AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28099502 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (standard regimen)
Number of subjects: 21
Study 28099502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide + Gemcitabine
Number of subjects: 21
Study 25885913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-driven walking programme
Number of subjects: 200
Study 25885913 — intervention group
Group type: EXPERIMENTAL
Intervention: Back care advice and education followed by pedometer-driven walking programme
Number of subjects: 200
Study 25885913 — intervention group
Group type: COMPARATOR
Intervention: Back care advice and education (Control)
Number of subjects: 200
Study 24004961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic inlay/onlay
Number of subjects: 400
Study 24004961 — intervention group
Group type: COMPARATOR
Intervention: Composite inlay/onlay
Number of subjects: 400
Study 22287304 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent
Number of subjects: 43
Study 22287304 — intervention group
Group type: COMPARATOR
Intervention: Control stent
Number of subjects: 43
Study 18719908 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-site PCI (n = 68)
Number of subjects: 128
Study 18719908 — intervention group
Group type: COMPARATOR
Intervention: On-site PCI (n = 60)
Number of subjects: 128
Study 16420567 — intervention group
Group type: COMPARATOR
Intervention: Standard dosage of rFVIIa (90 microg kg(‐1), repeated every 3 h)
Number of subjects: 20
Study 16420567 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage of rFVIIa (270 microg kg(‐1), single dose)
Number of subjects: 20
Study 15520310 — intervention group
Group type: COMPARATOR
Intervention: Circumferential pulmonary vein ablation (CPVA) alone (group 1)
Number of subjects: 560
Study 15520310 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified circumferential pulmonary vein ablation (group 2)
Number of subjects: 560
Study 11751698 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (0.5 and 3 ng/kg per minute)
Number of subjects: 121
Study 9015016 — intervention group
Group type: EXPERIMENTAL
Intervention: U removal technique
Number of subjects: 24
Study 9015016 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 24
Study 8392297 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam (slow-release form)
Number of subjects: 27
Study 8392297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3080871 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (60 mEq/L sodium, 20 mEq/L potassium, 50 mEq/L chloride, 30 mEq/L citrate, 20 g/L glucose, 5 g/L fructose)
Number of subjects: 29
Study 3080871 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy
Number of subjects: 29
Study 3080871 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rehydration therapy
Number of subjects: 29
Study 30299024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance therapy (DT)
Number of subjects: 0
Study 30299024 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group (Control)
Number of subjects: 0
Study 29695208 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified GnRH agonist protocol (group A)
Number of subjects: 116
Study 29695208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild stimulation protocol (group B)
Number of subjects: 116
Study 29695208 — intervention group
Group type: EXPERIMENTAL
Intervention: Antagonist protocol (group C)
Number of subjects: 116
Study 29695208 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 116
Study 27955644 — intervention group
Group type: EXPERIMENTAL
Intervention: Stypro hemostatic sponge
Number of subjects: 0
Study 27955644 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hemostatic sponge
Number of subjects: 0
Study 27955644 — intervention group
Group type: COMPARATOR
Intervention: Gelatin sponge
Number of subjects: 0
Study 24814202 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PRO)
Number of subjects: 95
Study 24814202 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (DEX)
Number of subjects: 95
Study 22349668 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) oral drops
Number of subjects: 80
Study 22349668 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral drops
Number of subjects: 80
Study 19703572 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon (glutamate receptor antagonist)
Number of subjects: 0
Study 19703572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18351483 — intervention group
Group type: EXPERIMENTAL
Intervention: Social comfort with EXPLORE participants
Number of subjects: 271
Study 18351483 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust of other EXPLORE participants
Number of subjects: 271
Study 18351483 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling detached from EXPLORE
Number of subjects: 271
Study 18351483 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception that EXPLORE participants are cunning
Number of subjects: 271
Study 16151341 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-channel paired stimulation with 5000 pps per channel
Number of subjects: 13
Study 16151341 — intervention group
Group type: COMPARATOR
Intervention: 16-channel sequential stimulation with 2500 pps per channel
Number of subjects: 13
Study 16151341 — intervention group
Group type: COMPARATOR
Intervention: 8-channel sequential stimulation with 5000 pps per channel
Number of subjects: 13
Study 12030996 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeds
Number of subjects: 54
Study 12030996 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluid
Number of subjects: 54
Study 12030996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 10098611 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG analysis in patients with schizophrenia
Number of subjects: 0
Study 10098611 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8533058 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (vigabatrin, lamotrigine, gabapentin, oxcarbazepine, felbamate)
Number of subjects: 0
Study 1975473 — intervention group
Group type: EXPERIMENTAL
Intervention: bucindolol
Number of subjects: 19
Study 1975473 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 837099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear-off calendar
Number of subjects: 46
Study 837099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet identification card
Number of subjects: 46
Study 837099 — intervention group
Group type: COMPARATOR
Intervention: Standard instructions
Number of subjects: 46
Study 31837105 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral distress measured using the Moral Distress Scale‐Revised (MDS‐R)
Number of subjects: 612
Study 31837105 — intervention group
Group type: EXPERIMENTAL
Intervention: High moral distress level
Number of subjects: 612
Study 30845333 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-polysaccharide conjugate vaccine (Vi-TCV)
Number of subjects: 32500
Study 28414267 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration low intensity ultrasound for active trapezius trigger points
Number of subjects: 0
Study 26423195 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out rapid HIV testing
Number of subjects: 83435
Study 26423195 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 83435
Study 23593139 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at acupoint (treatment group)
Number of subjects: 100
Study 23593139 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture at non-acupoint (control group)
Number of subjects: 100
Study 21768545 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing strategy
Number of subjects: 2368
Study 20110037 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of bicalutamide 50-mg tablets
Number of subjects: 34
Study 20110037 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of bicalutamide 50-mg tablets
Number of subjects: 34
Study 20110037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 34
Study 16919575 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress gated SPECT regional wall motion abnormality
Number of subjects: 27
Study 16919575 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress gated SPECT LVEF
Number of subjects: 27
Study 17136995 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium, an inhaled anticholinergic, with once-daily dosing for four years.
Number of subjects: 0
Study 17136995 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 11718031 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 5 mg (Group A)
Number of subjects: 39
Study 11718031 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg (Group B)
Number of subjects: 39
Study 11718031 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 5 mg or 10 mg
Number of subjects: 39
Study 9521944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual abuse during childhood
Number of subjects: 1026
Study 9521944 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidents of physical abuse
Number of subjects: 1026
Study 9521944 — intervention group
Group type: EXPERIMENTAL
Intervention: Major physical abuse or emotional abuse
Number of subjects: 1026
Study 8296850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K1 (17 mothers)
Number of subjects: 33
Study 8296850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (16 mothers)
Number of subjects: 33
Study 2574626 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg) twice daily
Number of subjects: 66
Study 2574626 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (60 mg) and phenylpropanolamine (50 mg) combination tablet twice daily
Number of subjects: 66
Study 167673 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH
Number of subjects: 0
Study 167673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31143019 — intervention group
Group type: EXPERIMENTAL
Intervention: Bhramari pranayama breathing exercise
Number of subjects: 60
Study 31143019 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment of chronic sinusitis
Number of subjects: 60
Study 30104102 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd+ areas with T2W hyperintensity (Gd+/T2high)
Number of subjects: 41
Study 30104102 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd+ areas with T2W isointensity (Gd+/T2iso)
Number of subjects: 41
Study 30104102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell density
Number of subjects: 41
Study 26180053 — intervention group
Group type: EXPERIMENTAL
Intervention: Real iTBS
Number of subjects: 18
Study 26180053 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 18
Study 24840766 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiorecorded visits with caregivers discussing caregiving problems and coping strategies
Number of subjects: 4
Study 23222963 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape consumption (46 g of lyophilized grape powder daily for four weeks)
Number of subjects: 24
Study 23222963 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical macronutrient composition and caloric value as GRAPE)
Number of subjects: 24
Study 20961828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IT)
Number of subjects: 100
Study 20961828 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 17027139 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior polymer crowns with glass-fiber framework (group 1)
Number of subjects: 80
Study 17027139 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior polymer crowns without glass-fiber framework (group 2)
Number of subjects: 80
Study 17027139 — intervention group
Group type: COMPARATOR
Intervention: Conventional metal-ceramic crowns (control group)
Number of subjects: 80
Study 16287792 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 303
Study 16287792 — intervention group
Group type: COMPARATOR
Intervention: Control (not receiving efavirenz)
Number of subjects: 303
Study 12428180 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer consumption (4 glasses for men, 3 glasses for women)
Number of subjects: 19
Study 12428180 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol beer (control)
Number of subjects: 19
Study 10401939 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of metoclopramide
Number of subjects: 10
Study 10401939 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 10
Study 7734367 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg cladribine/m2/d
Number of subjects: 102
Study 7734367 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg cladribine/m2/d
Number of subjects: 102
Study 7734367 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (3.4 mg/m2 or 0.085 mg/kg)
Number of subjects: 102
Study 2193636 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU)
Number of subjects: 0
Study 2193636 — intervention group
Group type: COMPARATOR
Intervention: Normal fT levels (control group)
Number of subjects: 0
Study 7398190 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg/70 kg body weight (intravenously or orally)
Number of subjects: 10
Study 7398190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6342648 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical PUVA with 2-h interval therapy (1% 8-methoxypsoralen followed by UV-A exposure 2 hours later)
Number of subjects: 15
Study 6342648 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical PUVA with non-interval therapy (1% 8-methoxypsoralen followed by UV-A exposure within 5 minutes)
Number of subjects: 15
Study 31594891 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 100
Study 31594891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 100
Study 30630792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of tranexamic acid and glutathione
Number of subjects: 180
Study 30630792 — intervention group
Group type: COMPARATOR
Intervention: Pure topical therapy of hydroquinone ointment
Number of subjects: 180
Study 27245981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 144
Study 24113563 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducational intervention (PIP)
Number of subjects: 238
Study 24113563 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 238
Study 22334123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicotine (0.5 and 1.0 mg/70 kg)
Number of subjects: 100
Study 22334123 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study 20817823 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed acceptance cues
Number of subjects: 0
Study 20817823 — intervention group
Group type: COMPARATOR
Intervention: Nonlonely individuals
Number of subjects: 0
Study 17716273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-modulated EMF exposure at 0.2 W kg(‐1)
Number of subjects: 15
Study 17716273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-modulated EMF exposure at 5 W kg(‐1)
Number of subjects: 15
Study 17716273 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 15
Study 15848570 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (Simulect)
Number of subjects: 56
Study 15848570 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 56
Study 15848570 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 12460126 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 600
Study 12460126 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 600
Study 12460126 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Support Network (FSN)
Number of subjects: 600
Study 12460126 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Community Reinforcement Approach (ACRA)
Number of subjects: 600
Study 12460126 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 600
Study 10509549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam at 0.04 microg/kg/min
Number of subjects: 33
Study 10509549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam at 0.8 microg/kg/min
Number of subjects: 33
Study 10509549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (general)
Number of subjects: 33
Study 10509549 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 33
Study 7859936 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bedtime insulin/daytime sulfonylurea (BI-DSU)
Number of subjects: 30
Study 7859936 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bedtime insulin plus daytime sulfonylurea (BI-DSU)
Number of subjects: 30
Study 7859936 — intervention group
Group type: COMPARATOR
Intervention: Low-dose bedtime insulin alone
Number of subjects: 30
Study 7859936 — intervention group
Group type: COMPARATOR
Intervention: Daytime sulfonylurea alone
Number of subjects: 30
Study 1659505 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 20
Study 1659505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 20
Study 1659505 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 20
Study 7278218 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth jump
Number of subjects: 160
Study 7278218 — intervention group
Group type: EXPERIMENTAL
Intervention: Box drill
Number of subjects: 160
Study 7278218 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility-agility exercise
Number of subjects: 160
Study 7278218 — intervention group
Group type: COMPARATOR
Intervention: Control (warmup)
Number of subjects: 160
Study 30820059 — intervention group
Group type: EXPERIMENTAL
Intervention: Endo-cut I mode
Number of subjects: 0
Study 30820059 — intervention group
Group type: COMPARATOR
Intervention: Swift-coagulation mode
Number of subjects: 0
Study 28176336 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic machine perfusion (HMP)
Number of subjects: 48
Study 28176336 — intervention group
Group type: COMPARATOR
Intervention: Common static cold preservation (CCP)
Number of subjects: 48
Study 28176336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 25873064 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus (trough levels 3-8 ng/mL) with reduced tacrolimus (trough levels <5 ng/mL)
Number of subjects: 330
Study 25873064 — intervention group
Group type: COMPARATOR
Intervention: standard tacrolimus (trough levels 6-10 ng/mL)
Number of subjects: 330
Study 23377343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment
Number of subjects: 20
Study 23377343 — intervention group
Group type: COMPARATOR
Intervention: Fat grafting
Number of subjects: 20
Study 21349680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention providing alliance and outcome feedback to counselors
Number of subjects: 1613
Study 19822825 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens plus medroxyprogesterone acetate (0.625 mg + 2.5 mg)
Number of subjects: 14538
Study 19822825 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens plus medroxyprogesterone acetate
Number of subjects: 14538
Study 19822825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14538
Study 16618486 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-messaging service (SMS) intervention for 12 weeks
Number of subjects: 51
Study 16618486 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 51
Study 15574078 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of beta-hydroxy beta-methylbutyrate (HMB) per day
Number of subjects: 26
Study 15574078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12954467 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Respiratory Insufficiency (SRI) Questionnaire
Number of subjects: 226
Study 10409125 — intervention group
Group type: EXPERIMENTAL
Intervention: DCA (100 mg/kg body mass)
Number of subjects: 6
Study 10409125 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 6
Study 8643332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-saccade trials with a cue lead time of 100 ms
Number of subjects: 5
Study 8643332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-saccade trials with a cue lead time of 200 ms
Number of subjects: 5
Study 8643332 — intervention group
Group type: COMPARATOR
Intervention: Test sessions without preinformative cues
Number of subjects: 5
Study 2384080 — intervention group
Group type: EXPERIMENTAL
Intervention: CM40907
Number of subjects: 6
Study 2384080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7317296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilators
Number of subjects: 0
Study 7317296 — intervention group
Group type: COMPARATOR
Intervention: Dust exposure (tea and wood)
Number of subjects: 0
Study 31559633 — intervention group
Group type: EXPERIMENTAL
Intervention: Early movement (EM) - tooth extracted 1 week before space closure initiation
Number of subjects: 25
Study 31559633 — intervention group
Group type: COMPARATOR
Intervention: Delayed movement (DM) - tooth extracted 8 weeks before space closure initiation
Number of subjects: 25
Study 31559633 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast movers - tooth movement ≥1 mm per month
Number of subjects: 25
Study 31559633 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow movers - tooth movement <1 mm per month
Number of subjects: 25
Study 11757002 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted system (active group)
Number of subjects: 31